Merck invests over €300M in new bioprocessing production center in Daejeon, South Korea

Merck, through its Life Science business sector, is investing more than €300 million in a new Bioprocessing Production Center in Daejeon, South Korea, expected to create approximately 300 additional jobs by the end of 2028.

“Expanding our presence in the region will bring us even closer to our customers in this evolving and dynamic market.”sigmaaldrich.com

• 1 source
• sigmaaldrich.comMilliporeSigma Invests More than € 300 Million in New Life Science Production Site in KoreaTimo BreinerMar 20, 2024

Summarized from public sources; check the original articles before acting on it.